Optimization of the use of B-type natriuretic peptide levels for risk stratification at discharge in elderly patients with decompensated heart failure

被引:20
|
作者
Cournot, Maxime [1 ,2 ]
Mourre, Fabien [1 ]
Castel, Fabienirie [3 ]
Ferrieres, Jean [2 ]
Destrac, Sylvain [1 ]
机构
[1] Ctr Hosp Val Ariege, Dept Cardiol, Foix, France
[2] INSERM, U558, Cardiovasc Epidemiol Unit, F-31073 Toulouse, France
[3] Ctr Hosp Val Ariege, Dept Gerontol, Foix, France
关键词
D O I
10.1016/j.ahj.2008.01.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background In elderly patients hospitalized for decompensated heart failure, B-type natriuretic peptide (BNP) levels at discharge and the change in BNP during hospitalization may provide different information and may need to be taken into account simultaneously to best reflect the response to therapy. The aim of this study was to determine whether the most accurate risk stratification is obtained using BNP level after stabilization on treatment, the change in BNP under optimal treatment, or a combination of both markers. Methods This prospective cohort study included 157 consecutive patients aged >= 70 (mean, 83 years), hospitalized for decompensated heart failure. Clinical, radiologic, biologic, and ultrasonography data were collected on admission and at discharge. Results The median BNP level on admission was 1,057 pg/mL, and the mean change during hospitalization was -42%. Cardiac death or readmission were independently predicted by both predischarge BNP (best threshold: >360 pq/mL, HR 3.35 [1.94-5.75]) and the change in BNP levels (best threshold: -50%, HR 2.52 [1.59-4.01]). The highest event rate was observed in patients with both a predischarge BNP >= 360 pg/mL and a decrease <50% during hospitalization (HR 5.97 [2.98-11.94] compared with patients with a predischarge BNP <360 pg/mL and a decrease >= 50%, after adjustment for potential confounders). The remaining patients constituted an intermediate risk group (HR 3.13 [1.44-6.77]). Conclusion Predischarge BNP and inhospital BNP change should not be interpreted independently from each other. The highest risk group includes patients with a high predischarge BNP level corresponding to more than the half of the BNP on admission. These patients would benefit from close monitoring for signs of decompensation.
引用
收藏
页码:986 / 991
页数:6
相关论文
共 50 条
  • [21] Obesity and suppressed B-type natriuretic peptide levels in heart failure
    Mehra, MR
    Uber, PA
    Park, MH
    Scott, RL
    Ventura, HO
    Harris, BC
    Frohlich, ED
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (09) : 1590 - 1595
  • [22] B-type natriuretic peptide levels and benign adiposity in obese heart failure patients
    Vasiliki Katsi
    Maria Marketou
    Alexios S. Antonopoulos
    Dimitrios Vrachatis
    Fragkiskos Parthenakis
    Dimitris Tousoulis
    Heart Failure Reviews, 2019, 24 : 219 - 226
  • [23] Predictors of absence of heart failure in patients with elevated B-type natriuretic peptide levels
    Knudsen, CW
    Clopton, P
    Klemsdal, TO
    Westheim, A
    Wu, A
    Abraham, WT
    Storrow, AB
    McCord, JK
    Nowak, RM
    McCullough, PA
    Omland, T
    CIRCULATION, 2004, 110 (17) : 368 - 368
  • [24] Prognosis of Stage A or B Heart Failure Patients With Elevated B-type Natriuretic Peptide Levels
    Daniels, Lori B.
    Clopton, Paul
    Jiang, Kevin
    Greenberg, Barry
    Maisel, Alan S.
    JOURNAL OF CARDIAC FAILURE, 2010, 16 (02) : 93 - 98
  • [25] B-type natriuretic peptide levels are not associated with health status in patients with heart failure
    Luther, SA
    McCullough, PA
    Rumsfeld, JS
    Jones, PG
    Peterson, ED
    Rathore, SS
    Havranek, EP
    Spertus, JA
    Masoudi, FA
    CIRCULATION, 2004, 109 (20) : E233 - E233
  • [26] B-type natriuretic peptide levels and benign adiposity in obese heart failure patients
    Katsi, Vasiliki
    Marketou, Maria
    Antonopoulos, Alexios S.
    Vrachatis, Dimitrios
    Parthenakis, Fragkiskos
    Tousoulis, Dimitris
    HEART FAILURE REVIEWS, 2019, 24 (02) : 219 - 226
  • [27] Usefulness of Inhospital change in B-type natriuretic peptide levels in predicting long-term outcome in elderly patients admitted for decompensated heart failure
    Cournot, Maxime
    Leprince, Philippe
    Destrac, Sylvain
    Ferrieres, Jean
    AMERICAN JOURNAL OF GERIATRIC CARDIOLOGY, 2007, 16 (01): : 8 - 14
  • [28] Predischarge measurement of B-type natriuretic peptide predicts outcome of patients admitted for decompensated heart failure
    Logeart, D
    Thabut, G
    Chavelas, C
    Beyne, P
    Saudubray, C
    Bouvier, E
    Solal, AC
    CIRCULATION, 2002, 106 (19) : 472 - 472
  • [29] Urinary B-type natriuretic peptide levels in the diagnosis and prognosis of heart failure patients
    Cortes, Raquel
    Rivera, Miguel
    Salvador, Antonio
    Juanatey, Jose Ramon
    Miro, Vicente
    Calabuig, Jose Ramon
    Lozano, Teresa
    Sogorb, Francisco
    Roselle, Esther
    Martinez Dolz, Luis
    Orosa, Placido
    Mora, Vicente
    Sevilla, Begona
    Climent, Vicente
    Almenar, Luis
    Jordan, Alejandro
    Garcia de Burgos, Fernando
    Valero, Ricardo
    Morillas, Pedro
    Bertomeu, Vicente
    Mainar, Luis
    Gomez, Ricardo
    Sancho Tello, Maria Jose
    Marin, Francisco
    Antorrena, Isabel
    Perez Bosca, Jose Luis
    Paya, Rafael
    Portoles, Manuel
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 44A - 44A
  • [30] Clinical significance of B-type natriuretic peptide in patient with acute decompensated heart failure
    Izumida, Toshihide
    Imamura, Teruhiko
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 329 : 152 - 152